EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Elly Vereyken

Work experience

1. Employer: Medicines Evaluation Board
   - Start date: 072020
   - End date:
   - Position: Clinical Assessor
   - Activities: Clinical assessor in the infectious disesases group.
   - Country: Netherlands
2. Employer: Janssen Biologics B.V.
   - Start date: 102018
   - End date: 072020
   - Position: Scientist
   - Activities: Working at the department of BioTD API, at the moment my priority is writing Module 3 sections for a BLA for a bispecific antibody, which is a first at the company. I have been involved in tech transfer of Phase 1 and 3 new product introductions to Leiden as both upstream and downstream lead. Furthermore, I lead the lean team of the department.
   - Country: Netherlands
3. Employer: Janssen Biologics B.V.
   - Start date: 062014
   - End date: 102018
   - Position: Senior Associate Scientist
   - Activities: I was involved in the life cycle management of two commercial products, Simponi and Stelara, e.g. to increase the efficiency of the 3.5L bioreactor model. I independently wrote protocols, reports, memo's and support events.
   - Country: Netherlands
4. Employer: AUTHOR!
   - Start date: 092012
   - End date: 052014
   - Position: Medical Writer
   - Activities: Writing and quality control of parts of common technical documents, briefing documents, investigator's brochure, clinical study reports, study protocols and informed consent forms for patients.
   - Country: Netherlands
5. Employer: Erasmus Medical Centre
   - Start date: 2011
   - End date: 2012
   - Position: Post_doctoral fellow
   - Activities: Project: Role of macrophages and monocytes in kidney transplantation. The aim was to determine the role of macrophages/monocytes after kidney transplantation.
   - Country: Netherlands
6. Employer: VU Medical Centre
   - Start date: 2010
   - End date: 2011
   - Position: Post_doctoral fellow
   - Activities: Project: Differently activated macrophages in Multiple Sclerosis The aim was to determine the mechanisms behind the diverse functions of differently activated macrophages (M1/CA and M2/AA) during the neurological damage observed during MS.
   - Country: Netherlands

Education and training

1. Subject: VU Medical Centre
   - Start date: 2005
   - End date: 2009
   - Qualification: PhD
   - Organisation: Project: The role of differently activated macrophages on axonal damage during multiple sclerosis.
   - Country: Netherlands
2. Subject: Utrecht University
   - Start date: 1999
   - End date: 2005
   - Qualification: Master Biomedical Sciences
   - Organisation: Clinical and Experimental Neurology including an extra internship at the Scripps Research Institute, USA
   - Country: Netherlands

Additional information

Publications

1) Human monocytes produce interferon_gamma upon stimulation with LPS, Kraaij MD, Vereyken EJ, Leenen PJ, van den Bosch TP, Rezaee F, Betjes MG, Baan CC, Rowshani AT; Cytokine. 2014 May;67(1):7_12. 2) Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status, Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, Amor S, Teunissen CE, van Horssen J, Dijkstra CD; J Neuroinflammation. 2013 Mar 4;10:35. 3) A shift towards pro_inflammatory CD16+ monocyte subsets with preserved cytokine

production potential after kidney transplantation, Vereyken EJ, Kraaij MD, Baan CC, Rezaee F, Weimar W, Wood KJ, Leenen PJ, Rowshani AT;. PLoS One. 2013 Jul 29;8(7):e70152. 4) The role of macrophage lineage cells in kidney graft rejection and survival, Rowshani AT, Vereyken EJ; Transplantation. 2012 Aug 27;94(4):309_18. 5) Classically and alternatively activated bone marrow derived macrophages differ in cytoskeletal functions and migration towards specific CNS cell types, Vereyken EJ, Heijnen PD, Baron W, de Vries EH, Dijkstra CD, Teunissen CE; J Neuroinflammation. 2011 May 26;8:58. 6) The release of cytokines by macrophages is not affected by myelin ingestion, Glim JE, Vereyken EJ, Heijnen DA, García Vallejo JJ, Dijkstra CD; Glia. 2010 Dec;58(16):1928_36. 7) An in vitro model for de_ and remyelination using lysophosphatidyl choline in rodent whole brain spheroid cultures, Vereyken EJ, Fluitsma DM, Bolijn MJ, Dijkstra CD, Teunissen CE; Glia. 2009 Sep;57(12):1326_40. 8) Axonale schade in multiple sclerose: oorzaken en biologische merkerstoffen, Teunissen C.E., Vereyken EJ; Neuropraxis. 2007 11:29_33. 9) Chronic interleukin_6 alters the level of synaptic proteins in hippocampus in culture and in vivo, Vereyken EJ, Bajova H, Chow S, de Graan PN, Gruol DL; Eur J Neurosci. 2007 Jun;25(12):3605_16.

Projects

Memberships

Other Relevant Information